Marja Dubay

831 total citations
14 papers, 567 citations indexed

About

Marja Dubay is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Marja Dubay has authored 14 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Hematology. Recurrent topics in Marja Dubay's work include Histone Deacetylase Inhibitors Research (9 papers), Acute Myeloid Leukemia Research (4 papers) and Protein Degradation and Inhibitors (3 papers). Marja Dubay is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), Acute Myeloid Leukemia Research (4 papers) and Protein Degradation and Inhibitors (3 papers). Marja Dubay collaborates with scholars based in United States, Canada and Switzerland. Marja Dubay's co-authors include Robert E. Martell, Claire Bonfils, Zuomei Li, Jeffrey M. Besterman, Ann Kalita, Gregory K. Reid, Willie Newsome, Guillermo Garcia‐Manero, Jörge E. Cortes and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemistry.

In The Last Decade

Marja Dubay

14 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marja Dubay United States 11 477 168 124 66 59 14 567
Chu Myong Seong South Korea 12 360 0.8× 133 0.8× 119 1.0× 20 0.3× 36 0.6× 30 511
P. Buhl-Jensen United Kingdom 10 467 1.0× 202 1.2× 59 0.5× 56 0.8× 18 0.3× 13 564
John S. Strader United States 4 582 1.2× 275 1.6× 384 3.1× 40 0.6× 54 0.9× 7 706
Tapan Bagui United States 10 370 0.8× 268 1.6× 44 0.4× 32 0.5× 29 0.5× 13 486
Aaron M. Domina United States 6 353 0.7× 143 0.9× 54 0.4× 45 0.7× 23 0.4× 9 429
Normand Richard United States 7 300 0.6× 64 0.4× 184 1.5× 14 0.2× 50 0.8× 12 436
Mylissa Borek United States 5 299 0.6× 109 0.6× 37 0.3× 44 0.7× 37 0.6× 10 367
Bettina Wingelhofer Austria 9 205 0.4× 123 0.7× 74 0.6× 42 0.6× 44 0.7× 12 377
Ernest Medina United States 6 444 0.9× 160 1.0× 89 0.7× 45 0.7× 34 0.6× 9 607
Seemana Bhattacharya United States 11 402 0.8× 168 1.0× 72 0.6× 22 0.3× 16 0.3× 23 483

Countries citing papers authored by Marja Dubay

Since Specialization
Citations

This map shows the geographic impact of Marja Dubay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marja Dubay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marja Dubay more than expected).

Fields of papers citing papers by Marja Dubay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marja Dubay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marja Dubay. The network helps show where Marja Dubay may publish in the future.

Co-authorship network of co-authors of Marja Dubay

This figure shows the co-authorship network connecting the top 25 collaborators of Marja Dubay. A scholar is included among the top collaborators of Marja Dubay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marja Dubay. Marja Dubay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Drouin, Michel, Christian Kollmannsberger, Hope E. Uronis, et al.. (2010). Daily administration of MGCD265 to patients with solid tumors in a dose-escalation phase I study (study 265-101).. Journal of Clinical Oncology. 28(15_suppl). 3106–3106. 1 indexed citations
2.
Besterman, Jeffrey M., Marielle Fournel, Isabelle Dupont, et al.. (2010). Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.. Journal of Clinical Oncology. 28(15_suppl). e13595–e13595. 17 indexed citations
3.
Fournel, Marielle, Isabelle Dupont, Claire Bonfils, et al.. (2010). Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor. Cancer Research. 70(8_Supplement). 3612–3612. 3 indexed citations
4.
Blum, Kristie A., Richard van der Jagt, Joseph Brandwein, et al.. (2009). Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. British Journal of Haematology. 147(4). 507–514. 94 indexed citations
5.
Liu, Jianhong, Claire Bonfils, Marja Dubay, et al.. (2008). Induction of an anti-angiogenesis factor, Thrombospondin 1 (TSP-1), by a novel histone deacetylase inhibitor, MGCD0103, in human cancer cells in vitro and in vivo. Cancer Research. 68. 739–739. 1 indexed citations
6.
Bonfils, Claire, Ann Kalita, Marja Dubay, et al.. (2008). Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay. Clinical Cancer Research. 14(11). 3441–3449. 81 indexed citations
7.
Garcia‐Manero, Guillermo, Sarit Assouline, Jörge E. Cortes, et al.. (2008). Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 112(4). 981–989. 194 indexed citations
8.
Younes, Anas, Michelle A. Fanale, Barbara Pro, et al.. (2007). A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. Journal of Clinical Oncology. 25(18_suppl). 8000–8000. 14 indexed citations
9.
10.
Younes, Anas, Peter McLaughlin, Charalambos Andreadis, et al.. (2007). Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.. Blood. 110(11). 2571–2571. 19 indexed citations
11.
12.
13.
Murthi, Krishna K., Marja Dubay, Leonardo Brizuela, et al.. (2000). Structure–activity relationship studies of flavopiridol analogues. Bioorganic & Medicinal Chemistry Letters. 10(10). 1037–1041. 42 indexed citations
14.
Xü, Takayuki Nakano, Scott Wick, Marja Dubay, & Leonardo Brizuela. (1999). Mechanism of Cdk2/Cyclin E Inhibition by p27 and p27 Phosphorylation. Biochemistry. 38(27). 8713–8722. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chu Myong Seong Breakdown of academic impact, for papers by P. Buhl-Jensen Breakdown of academic impact, for papers by John S. Strader Breakdown of academic impact, for papers by Tapan Bagui Breakdown of academic impact, for papers by Aaron M. Domina Breakdown of academic impact, for papers by Normand Richard Breakdown of academic impact, for papers by Mylissa Borek Breakdown of academic impact, for papers by Bettina Wingelhofer Breakdown of academic impact, for papers by Ernest Medina Breakdown of academic impact, for papers by Seemana Bhattacharya
Rankless by CCL
2026